Ann: COVID-19 Trading Update 110 - Week Ended 22 April 2022, page-6

Multiples can be voodo but I always felt at the peak of $4 there abouts the book to market cap multiple was excessive.

Since then it has come down but still I am unsure if the market would dictate more losses.

The market has repriced growth stocks and I'll be considering buying more into the future if TYR revenue is growing 10% there abouts in the next 2 - 3 years.

If it can grow its revenue by pursuing different verticals away from non-discretionary spending that would be great with a recession looming. Once the recession is over it would be a valuable company when discretionary spending recovers. The purchase of Medipass is a step in the right direction and its true value hasn't been realised.

If revenue does become stagnant during this looming recession I think there would be a few lost years and might not increase my position.